Lineage Cell Therapeutics Overview
Latest P/E ratio for Lineage Cell Therapeutics: -3.91 — see history and peer comparisons.
Get informed when a big investor buys or sells
+ Follow-3.91
The P/E ratio compares a company's stock price to its earnings per share. A lower P/E ratio may indicate that the stock is undervalued.
The latest P/E ratio for LCTX is -3.91. That is below the Healthcare sector average of 27.42. Investors often review this figure alongside Lineage Cell Therapeutics's historical trend and sector peers before judging valuation or financial health.
Against Healthcare companies, LCTX currently prints -3.91 for P/E ratio, while the sector average sits near 27.42. That is roughly 114.3% below the sector mean. Large gaps often invite a closer look at Lineage Cell Therapeutics's growth, margins, and balance sheet.
A P/E ratio of -3.91 for Lineage Cell Therapeutics is not 'good' or 'bad' on its own. Compare it with the peer average (27.42) and with LCTX's multi-year chart on this page. Persistently elevated multiples need growth or quality to justify them; depressed multiples need a catalyst or evidence the business is misunderstood.
After noting LCTX's P/E ratio (-3.91), review year-over-year change, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.
This page's peer comparison chart is the fastest way to stack Lineage Cell Therapeutics's P/E ratio against similar Healthcare names. You can also browse sector and industry screens on Stockcircle for a broader set of Healthcare companies and their key multiples and fundamentals.
